tocilizumab · Actemra / RoActemra
Monoclonal antibody
Biosimilars tracked: BAT1806, CT-P47 (tocilizumab)
Evidence outlook
Approved: Rheumatoid Arthritis, COVID-19
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (7)
- ACTEMRA (tocilizumab), giant cell arteritis: Adult patients with giant cell arteritis.
- ACTEMRA (tocilizumab), systemic sclerosis-associated interstitial lung disease: Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
- ACTEMRA (tocilizumab), polyarticular juvenile idiopathic arthritis: Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.
- ACTEMRA (tocilizumab), systemic juvenile idiopathic arthritis: Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
- ACTEMRA (tocilizumab), cytokine release syndrome: Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome.
- Rheumatoid arthritis (RoActemra)
- Rheumatoid arthritis (Actemra, Chugai; earlier Japan approval for Castleman's disease in 2005)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03155347 NCT03155347 · Rheumatoid Arthritis This randomized, double-blind, active-comparator trial of 340 participants met its primary endpoint: about half of tocilizumab-treated patients achieved an ACR20 response at 24 weeks, compared with a quarter on methotrexate alone, a highly statistically significant difference for both the combination and monotherapy arms. Registry: NCT03155347 | 3 | Percentage of Participants With an American College of Rheumatology (ACR) 20 (ACR20) Response at Week 24 2022-08-08 | ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001 | Reliable signal | link ↗ |
View 12 more trials
NCT01941095 NCT01941095 · Rheumatoid Arthritis The study was a single-group, open-label trial without randomization, blinding, or a comparator arm, so improvement cannot be separated from the natural course of disease or other treatment effects. Its clinical remission endpoint was reported descriptively in 80 evaluable participants, with no formal between-group comparison. Registry: NCT01941095 | 3 | Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24 2016-07-10 | Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24 (Week 24): Tocilizumab 40% | Weak signal | link ↗ |
NCT02031471 NCT02031471 · Rheumatoid Arthritis The study was a single-arm, open-label trial without randomization, blinding, or a placebo/active comparator. Although the clinical disease activity endpoint improved, the absence of a comparison group means the result cannot reliably distinguish treatment effects from other influences. Registry: NCT02031471 | 3 | Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS) (From baseline to Week 24); Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Per Protocol Set (PPS) (From baseline to Week 24) 2015-09 | Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS) (From baseline to Week 24): Tocilizumab — Baseline (n=56): 5.55 Units on a scale (Standard Deviation 1.17); Change at Week 24 (n=42): -3.24 Units on a scale (Standard Deviation 1.47) | Weak signal | link ↗ |
NCT00144508 NCT00144508 · Rheumatoid Arthritis Registry: NCT00144508 | 3 | Change in the erosion score, as determined by the modified Sharp method. (week 52); Frequency and severity of adverse events and adverse drug reactions (throughout study) 2004-05 | Mean week-52 change in total modified Sharp score was 2.3 on tocilizumab vs 6.1 on DMARDs (p<0.01). | not yet graded | link ↗ |
NCT00144521 NCT00144521 · Rheumatoid Arthritis Registry: NCT00144521 | 3 | Frequency of ACR 20% improvement (week 24) 2004-08 | ACR20 at week 24 was 80.3% with tocilizumab vs 25.0% in the control group. | not yet graded | link ↗ |
NCT00109408 NCT00109408 · Rheumatoid Arthritis This was a randomized, double-blind, double-dummy trial against an active comparator, methotrexate, and the published report shows tocilizumab gave more ACR20 responses at week 24 (69.9% vs 52.5%, p<0.001). The trial reported a power calculation of 275 patients per arm and randomized 286 and 284 patients to the two main arms. Registry: NCT00109408 | 3 | Percentage of patients with ACR 20 response (Week 24) 2007-12 | Results not posted; external-source review pending | Reliable signal | link ↗ |
NCT00106535 NCT00106535 · Rheumatoid Arthritis This was a large, randomised, double-blind, placebo-controlled phase 3 trial in which both tocilizumab doses beat placebo plus methotrexate on every primary endpoint: ACR20 response at week 24 (56.3% and 50.6% vs 27.0%, p<0.0001), change in the modified Sharp-Genant radiographic score at week 52 (0.29 and 0.34 vs 1.13, p<0.0001), and cumulative HAQ-DI disability over 52 weeks (p<0.0001). The design is strong, but the registry entry does not report a sample-size or power calculation for the primary endpoint, so the trial cannot be confirmed as adequately powered from the record available. Registry: NCT00106535 | 3 | Percentage of Participants With American College of Rheumatology-ACR20 Response (Baseline, Week 24); Change From Baseline in Modified Total Sharp-Genant Score at Week 52 (Baseline, Week 52); Change in Physical Function as Measured by the Area Under the Curve (AUC) for the Change From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 52 (Baseline to Week 52); Change From Baseline in the Modified Total Sharp-Genant Score at Week 104 (Baseline, Week 104); Change in Physical Function as Measured by the Area Under the Curve for the Change From Baseline in the Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 104 (Baseline to Week 104) 2007-05 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT00106548 NCT00106548 · Rheumatoid Arthritis This was a randomized, double-blind, placebo-controlled trial of 623 patients, and the published report shows more ACR20 responses at week 24 with tocilizumab 8 mg/kg (59%) and 4 mg/kg (48%) than with placebo (26%), p<0.0001 for both. No power calculation was reported in the sources checked, so it cannot be confirmed that the trial enrolled the number of patients it planned for. Registry: NCT00106548 | 3 | Percentage of patients with ACR 20 response (Week 24) | Results not posted; external-source review pending | Partial signal | link ↗ |
NCT00106574 NCT00106574 · Rheumatoid Arthritis This was a large randomized, double-blind, placebo-controlled trial, and its primary endpoint, ACR20 response at Week 24, was clearly met. However, no sample-size or power calculation is reported in the sources available for this trial, so it cannot be confirmed that it was adequately powered. Registry: NCT00106574 | 3 | Percentage of patients with ACR 20 response (Week 24) 2007-12 | Results not posted; external-source review pending | Partial signal | link ↗ |
NCT00106522 NCT00106522 · Rheumatoid Arthritis This was a randomized, double-blind, placebo-controlled trial in 499 patients. The primary endpoint, ACR20 response at week 24, was significantly better with both tocilizumab doses than with placebo (p<0.001). The published sample-size calculation required 450 patients, and 499 were randomized. Registry: NCT00106522 | 3 | Percentage of patients with ACR 20 response (Week 24); AEs, laboratory parameters, vital signs, ECGs. (Throughout study) 2007-11 | Results not posted; external-source review pending | Reliable signal | link ↗ |
NCT01194414 NCT01194414 · Rheumatoid Arthritis SUMMACTA was a randomized, double-blind, double-dummy Phase 3 trial in 1,262 patients with rheumatoid arthritis and an inadequate response to DMARDs, comparing subcutaneous with intravenous tocilizumab. The efficacy primary was non-inferiority of the subcutaneous form for ACR20 response at week 24, with a 12% margin. ACR20 response was 69.4% vs 73.4% (difference -4.0%, 95% CI -9.2 to 1.2), and the paper states the margin was met, so the primary was met. The other registered primary counts adverse events and carries no test. Source: Burmester et al., Ann Rheum Dis 2014. Registry: NCT01194414 | 3 | Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR20) Response at Week 24 (Baseline, 24 weeks); Percentage of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Assessments (Baseline to up to 3 months after last dose of study drug (approximately up to 2 years)) 2012-01 | ACR20 response at week 24, tocilizumab 162 mg SC weekly vs tocilizumab 8 mg/kg IV every 4 weeks: 69.4% (95% CI 65.5 to 73.2) vs 73.4% (95% CI 69.6 to 77.1); weighted difference -4.0% (95% CI -9.2 to 1.2), within the 12% non-inferiority margin (Burmester et al., Ann Rheum Dis 2014). | Partial signal | link ↗ |
NCT01232569 NCT01232569 · Rheumatoid Arthritis This was a randomized, double-blind, placebo-controlled trial, and tocilizumab gave clearly more ACR20 responses at week 24 than placebo (60.9% vs 31.5%, p<0.001). The trial reported a power calculation requiring 600 patients and randomized 656. Registry: NCT01232569 | 3 | Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (Baseline to Week 24) 2012-05 | Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (Baseline to Week 24): Tocilizumab 162 mg sc 60.9% (95% CI 56.3 to 65.4) vs Placebo sc 31.5% (95% CI 25.4 to 37.7) | Reliable signal | link ↗ |
NCT01331837 NCT01331837 · Rheumatoid Arthritis Registry: NCT01331837 | 4 | Time to First Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event (From baseline up to 4.9 years); Percentage of Patients Reporting a Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event (From baseline up to 4.9 years); Time to First CV-EAC Adjudicated Event - Sensitivity Analysis (From Baseline up to 4.9 years); Percentage of Patients With a CV-EAC Adjudicated Event - Sensitivity Analysis (From Baseline up to 4.9 years); Time to First CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity Analysis (From baseline up to 4.9 years); Percentage of Patients With a CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity Analysis (From baseline up to 4.9 years); Time to First CV-EAC Adjudicated Event Before Last Direct Contact Date (From Baseline up to 4.9 years); Percentage of Participants With a CV-EAC Adjudicated Event Before Last Direct Contact Date (From Baseline up to 4.9 years) 2016-03-25 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (125)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (106)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (37)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (73)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (57)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (26)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (20)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (1)
What this study did
Appears in other studies (5)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other IL-6 receptor drugs
BAT1806, Sarilumab, Levilimab. Compare all 4 IL-6 receptor drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for COVID-19: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tocilizumab (Actemra / RoActemra): this drug | Approved | Monoclonal antibody | IL-6 receptor | Partial signal | NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36) | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1806 (Tofidence) | Approved | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Elasomeran (Spikevax) | Approved | Vaccine | SARS-CoV-2 spike protein | Reliable signal | No reviewed efficacy summary in this indication | |
| Azvudine (FNC) | Phase 3 | Small molecule | HIV reverse transcriptase | not yet graded | No reviewed efficacy summary in this indication | |
| Ibuzatrelvir | Phase 3 | Small molecule | SARS-CoV-2 3CL protease | not yet graded | No reviewed efficacy summary in this indication | |
| Levilimab (Ilsira) | Phase 3 | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 2 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4396687 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(80 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Actemra / RoActemra (tocilizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.